AdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment.
AdvanCell CEO Philina Lee (L) with colleagues
July 15, 2026 11:25 AM EDT
Financing
Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger
Lei Lei Wu
Fierce Pharma Asia—GSK, Merck ADCs’ trial wins; AZ’s $1.5B EGFR buy; Biotechs’ new patent tricks
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca
AdvanCell, un’azienda farmaceutica di fase clinica specializzata in radiofarmaci e che si dedica allo sviluppo di terapie alfa…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a…
Viridian Therapeutics has scored an FDA
Pfizer's sigvotatug vedotin fails Phase 3 lung cancer trial, the third Seagen-acquired ADC to disappoint in roughly a year.
